Effects of compound traditional Astragalus and Salvia Miltiorrhiza extract on acute and chronic hepatic injury

• 발행기관: 셀메드 세포교정의약학회
• 저자명: Xiaoxiang Zhang Yan Yang Xin Liu Chao Wu Minzhu Chen
• 간행물 정보: 『셀메드』Volume 3 Issue 2, 1~5쪽, 전체 5쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2013.05.31

영문 초록

Previous reports showed that Compound Astragalus and Salvia miltiorrhiza extract (CASE), which was mainly composed of astragalosides, astragalus polysaccharide and salvianolic acids, inhibited hepatic fibrosis by mediating transforming growth factor-β (TGF-β)/Smad signaling. Our aim was to examine the effects of CASE on D-galactosamine (D-GalN) treated liver injury in mice and carbon tetrachloride (CCl4)-induced liver fibrosis in rats. CASE was administered to mice with D-GalN-induced liver injury and to rats with CCl4-induced liver fibrosis, respectively. Liver injury was routinely evaluated by relative liver weight, serum levels of ALT, AST, hyaluronic acid (HA), hepatic malondialdehyde (MDA) content, superoxide dismutase (SOD) activity, hydroxyproline (HYP) and histopathologic changes. Treatment of mice with CASE (60, 120, and 240 mg/kg, ig) significantly lowered ALT, relative liver weight, and MDA levels when compared with D-GalN treated mice. CASE (120, 240 mg/kg) significantly lowered ALT, AST, HA, HYP, and MDA levels against CCl4 treated rats. Decreased SOD level was reversed with CASE treatment. Upon histopathological examination, CASE treatment had significantly inhibitory effect on the progression of hepatic fibrosis in rats. These results indicate that CASE might be effective in treatment and prevention of acute and chronic hepatic injury due to its antioxidant activity.

키워드

compound Astragalus and Salvia miltiorrhiza extract hepatic injury antioxidant